Skip to Main Content

A version of this story originally appeared in The Readout, STAT’s biotech newsletter. Sign up here.

Dr. David Hung has had a distinguished career in biotech, presiding over the development of a blockbuster cancer drug and flipping a company for $14 billion. But the last act, in which he led an Alzheimer’s disease startup through a catastrophic failure, is one from which he’d like to move on.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • NELO data will be spectacular
    Its from the ARNA labs
    GPCR technology is 3 for 3 all best in class
    Ralenepig
    Entresimod
    Belviq
    Soon Apd 371 Non opioid pain Non addictive

    He left too soon

  • Jumping on Axovant ship he proved that the first time around he got either unbelievably lucky, or he was just a street smart. Either way, he must be a mediocre scientist/physician.

Comments are closed.